Nicholas Donoghoe, M.D.

As Executive Vice President, Chief Business and Strategy Officer (CBSO) at AbbVie, Dr. Nicholas Donoghoe leads Business Development, Corporate Strategy, and Business Technology Operations.

Dr. Donoghoe is focused on establishing strategies and external partnerships across the development continuum that will benefit patients and fuel scientific progress. Under his leadership, AbbVie has completed over $20 billion in external innovation deals since 2023. The Corporate Strategy team has also been instrumental in implementing strategies with the aim of maximizing our R&D efforts.

Additionally, he leads global Business Technology Operations, which includes more than 2,000 individuals dedicated to building new internal capabilities that help deliver remarkable therapies more efficiently and effectively, including leveraging digital technology and artificial intelligence (AI) to unlock new opportunities across our business—from drug discovery to commercial applications—and better serve our patients.

Dr. Donoghoe’s distinguished career includes leadership roles across AbbVie’s R&D and Commercial organizations. Prior to his time at AbbVie, he was a partner at McKinsey & Co. He holds an M.D. from Johns Hopkins School of Medicine.